Completed PHASE1 INTERVENTIONAL 1-arm NCT01831505

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System

Sponsor: Fred Hutchinson Cancer Center

Conditions Lymphoma

Interventions Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them

Updated 7 times since 2017 Last updated: Feb 24, 2017 Started: Nov 30, 2012 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01831505, this PHASE1 trial focuses on Lymphoma and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Mar 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2017 — Mar 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Presage Biosciences

Data source: Presage Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States